2021
Treatment of Pediatric Adrenocortical Carcinoma With Surgery, Retroperitoneal Lymph Node Dissection, and Chemotherapy: The Children's Oncology Group ARAR0332 Protocol
Rodriguez-Galindo C, Krailo MD, Pinto EM, Pashankar F, Weldon CB, Huang L, Caran EM, Hicks J, McCarville MB, Malkin D, Wasserman JD, de Oliveira Filho AG, LaQuaglia MP, Ward DA, Zambetti G, Mastellaro MJ, Pappo AS, Ribeiro RC. Treatment of Pediatric Adrenocortical Carcinoma With Surgery, Retroperitoneal Lymph Node Dissection, and Chemotherapy: The Children's Oncology Group ARAR0332 Protocol. Journal Of Clinical Oncology 2021, 39: 2463-2473. PMID: 33822640, PMCID: PMC8462560, DOI: 10.1200/jco.20.02871.Peer-Reviewed Original ResearchConceptsRetroperitoneal lymph node dissectionLymph node dissectionOutcomes of patientsAdrenocortical carcinomaNode dissectionStage IOncology GroupStage IV adrenocortical carcinomaStage-III adrenocortical carcinomaPediatric-specific studiesStage II diseaseEvent-free survivalStage II patientsThird of patientsOverall survival estimatesChildren's Oncology GroupHigh-risk groupCombination of mitotaneAggressive pediatric malignancyPediatric adrenocortical carcinomaAdvanced diseaseII patientsMultivariable analysisPoor outcomeExcellent outcomes
2020
Outcomes of adolescent males with extracranial metastatic germ cell tumors: A report from the Malignant Germ Cell Tumor International Consortium
Shaikh F, Stark D, Fonseca A, Dang H, Xia C, Krailo M, Pashankar F, Rodriguez‐Galindo C, Olson TA, Nicholson JC, Murray MJ, Amatruda JF, Billmire D, Stoneham S, Frazier AL. Outcomes of adolescent males with extracranial metastatic germ cell tumors: A report from the Malignant Germ Cell Tumor International Consortium. Cancer 2020, 127: 193-202. PMID: 33079404, DOI: 10.1002/cncr.33273.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsChildChild, PreschoolHumansInfantInfant, NewbornLymphatic MetastasisMaleMediastinal NeoplasmsNeoplasms, Germ Cell and EmbryonalProgression-Free SurvivalRetroperitoneal NeoplasmsRetrospective StudiesTesticular NeoplasmsYoung AdultConceptsMetastatic germ cell tumorsEvent-free survivalGerm cell tumorsCell tumorsRisk groupsYoung adultsAge groupsMale patientsAdolescent patientsAdolescent malesCox proportional hazards analysisMalignant germ cell tumorsIndividual patient databasePlatinum-based chemotherapyProportional hazards analysisYoung adult patientsClinical trial organizationsAdolescent age groupPediatric cooperative groupsTreatment of adolescentsDifferent age groupsAdult patientsClinical characteristicsEFS rateInclusion criteria
2019
Treatment of Childhood Nasopharyngeal Carcinoma With Induction Chemotherapy and Concurrent Chemoradiotherapy: Results of the Children's Oncology Group ARAR0331 Study.
Rodriguez-Galindo C, Krailo MD, Krasin MJ, Huang L, McCarville MB, Hicks J, Pashankar F, Pappo AS. Treatment of Childhood Nasopharyngeal Carcinoma With Induction Chemotherapy and Concurrent Chemoradiotherapy: Results of the Children's Oncology Group ARAR0331 Study. Journal Of Clinical Oncology 2019, 37: 3369-3376. PMID: 31553639, PMCID: PMC6920031, DOI: 10.1200/jco.19.01276.Peer-Reviewed Original ResearchConceptsEvent-free survivalChildhood nasopharyngeal carcinomaInduction chemotherapyConcurrent chemoradiotherapyStage IIBNasopharyngeal carcinomaCycles of ICCancer stage IIBPediatric-specific studiesCycles of cisplatinOverall survival estimatesAmerican Joint CommitteeDoses of cisplatinCumulative incidence estimatesRadiation dose reductionAdult regimensStable diseaseAdvanced diseasePartial responseMedian ageExcellent outcomesIncidence estimatesDose reductionPatientsJoint CommitteeOutcomes of adolescent males with extracranial malignant germ cell tumors compared with children and young adults: A report from the Malignant Germ Cell Tumors International Consortium (MaGIC) group.
Shaikh F, Stark D, Dang H, Xia C, Krailo M, Stenning S, Pashankar F, Rodriguez-Galindo C, Olson T, Hale J, Depani S, Stoneham S, Nicholson J, Murray M, Amatruda J, Billmire D, Fonseca A, Frazier A. Outcomes of adolescent males with extracranial malignant germ cell tumors compared with children and young adults: A report from the Malignant Germ Cell Tumors International Consortium (MaGIC) group. Journal Of Clinical Oncology 2019, 37: 10022-10022. DOI: 10.1200/jco.2019.37.15_suppl.10022.Peer-Reviewed Original ResearchMalignant germ cell tumorsExtracranial malignant germ cell tumorsEvent-free survivalGerm cell tumorsYoung adultsAdolescent patientsCell tumorsCox proportional hazards analysisIndividual patient databaseCox multivariable analysisPlatinum-based chemotherapyProportional hazards analysisYoung adult patientsPediatric cooperative groupsAdult patientsClinical characteristicsSame regimensMale patientsMultivariable analysisInclusion criteriaPatientsPatient databaseAge groupsAdult groupAdolescent malesAlfa-feto protein (AFP) as a predictor of outcome for children with germ cell tumors: A report from the malignant germ cell international consortium.
O'Neill A, Xia C, Krailo M, Shaikh F, Pashankar F, Billmire D, Olson T, Amatruda J, Villaluna D, Malogolowkin M, Rodriguez-Galindo C, Frazier A. Alfa-feto protein (AFP) as a predictor of outcome for children with germ cell tumors: A report from the malignant germ cell international consortium. Journal Of Clinical Oncology 2019, 37: 10036-10036. DOI: 10.1200/jco.2019.37.15_suppl.10036.Peer-Reviewed Original ResearchEvent-free survivalGerm cell tumorsAFP declinePediatric patientsCell tumorsTumor marker declineStart of chemotherapyDays of chemotherapyStandard-risk diseaseYears of ageAdult patientsRisk diseasePoor prognosisSerum AFPMarker declineStratified analysisPatientsChemotherapyTumorsInitial daysDaysDeclinePrognosisDisease
2018
Is carboplatin-based chemotherapy as effective as cisplatin-based chemotherapy in the treatment of advanced-stage dysgerminoma in children, adolescents and young adults?
Shah R, Xia C, Krailo M, Amatruda JF, Arul SG, Billmire DF, Brady WE, Covens A, Gershenson DM, Hale JP, Hurteau J, Murray MJ, Nicholson JC, Olson TA, Pashankar F, Rodriguez-Galindo C, Shaikh F, Stark D, Frazier AL, Stoneham S. Is carboplatin-based chemotherapy as effective as cisplatin-based chemotherapy in the treatment of advanced-stage dysgerminoma in children, adolescents and young adults? Gynecologic Oncology 2018, 150: 253-260. PMID: 29884437, DOI: 10.1016/j.ygyno.2018.05.025.Peer-Reviewed Original ResearchConceptsCisplatin-based chemotherapyClinical trial organizationsGerm cell tumorsFive-year event-free survivalMalignant ovarian germ cell tumorsOvarian germ cell tumorsAge groupsCarboplatin-based chemotherapyTreatment-related toxicityEvent-free survivalEligible patientsExcellent OSMetastatic diseaseOverall survivalClinical outcomesFrontline treatmentSurvival outcomesMean agePeak incidenceCell tumorsDysgerminomaChemotherapyPatientsTrials OrganizationCarboplatinComparison of carboplatin versus cisplatin in the treatment of paediatric extracranial malignant germ cell tumours: A report of the Malignant Germ Cell International Consortium
Frazier AL, Stoneham S, Rodriguez-Galindo C, Dang H, Xia C, Olson TA, Murray MJ, Amatruda JF, Shaikh F, Pashankar F, Billmire D, Krailo M, Stark D, Brougham MFH, Nicholson JC, Hale JP. Comparison of carboplatin versus cisplatin in the treatment of paediatric extracranial malignant germ cell tumours: A report of the Malignant Germ Cell International Consortium. European Journal Of Cancer 2018, 98: 30-37. PMID: 29859339, DOI: 10.1016/j.ejca.2018.03.004.Peer-Reviewed Original ResearchConceptsChildren's Oncology GroupEvent-free survivalOncology GroupClinical trialsGerm cell tumor patientsCarboplatin-based regimensCisplatin-based regimensParametric cure modelsLeukemia groupTumor patientsStandard riskChildren's CancerRegimensCancerRiskTrialsGroupCure modelPatientsCarboplatinInternational ConsortiumCisplatinOvarian Yolk Sac Tumors; Does Age Matter?
Conter C, Xia C, Gershenson D, Hurteau J, Covens A, Pashankar F, Krailo M, Billmire D, Patte C, Fresneau B, Shaikh F, Stoneham S, Nicholson J, Murray M, Frazier AL. Ovarian Yolk Sac Tumors; Does Age Matter? International Journal Of Gynecological Cancer 2018, 28: 77-84. PMID: 29194189, DOI: 10.1097/igc.0000000000001149.Peer-Reviewed Original ResearchConceptsOvarian yolk sac tumorEvent-free survivalYolk sac tumorOverall survivalSac tumorClinical trialsOvarian germ cell tumorsPreoperative alpha-fetoprotein levelAge cut pointStage IV diseaseAdverse prognostic factorPlatinum-based chemotherapyAlpha-fetoprotein levelsCut pointsGerm cell tumorsPediatric clinical trialsRisk of eventsOptimal cut pointJoint pediatricChemosensitive tumorsChemotherapeutic regimenPrognostic impactPrognostic factorsAdult trialsGynecologic oncologists
2017
Gonadal dysgenesis is associated with worse outcomes in patients with ovarian nondysgerminomatous tumors: A report of the Children's Oncology Group AGCT 0132 study
Dicken BJ, Billmire DF, Krailo M, Xia C, Shaikh F, Cullen JW, Olson TA, Pashankar F, Malogolowkin MH, Amatruda JF, Rescorla FJ, Egler RA, Ross JH, Rodriguez‐Galindo C, Frazier AL. Gonadal dysgenesis is associated with worse outcomes in patients with ovarian nondysgerminomatous tumors: A report of the Children's Oncology Group AGCT 0132 study. Pediatric Blood & Cancer 2017, 65 PMID: 29286555, PMCID: PMC6219870, DOI: 10.1002/pbc.26913.Peer-Reviewed Original ResearchConceptsOvarian germ cell tumorsMalignant ovarian germ cell tumorsGerm cell tumorsEvent-free survivalNon-GD patientsOverall survivalGonadal dysgenesisMalignant germ cell tumorsAggressive chemotherapy regimenHigh-risk groupNondysgerminomatous tumorsChemotherapy regimenPure dysgerminomaPediatric patientsSac tumorBilateral gonadectomyCell tumorsWorse outcomesEmbryonal carcinomaPatientsStreak ovariesDysgenetic gonadsTumorsY chromosome materialGonadoblastomaReduced and Compressed Cisplatin-Based Chemotherapy in Children and Adolescents With Intermediate-Risk Extracranial Malignant Germ Cell Tumors: A Report From the Children’s Oncology Group
Shaikh F, Cullen JW, Olson TA, Pashankar F, Malogolowkin MH, Amatruda JF, Villaluna D, Krailo M, Billmire DF, Rescorla FJ, Egler RA, Dicken BJ, Ross JH, Schlatter M, Rodriguez-Galindo C, Frazier AL. Reduced and Compressed Cisplatin-Based Chemotherapy in Children and Adolescents With Intermediate-Risk Extracranial Malignant Germ Cell Tumors: A Report From the Children’s Oncology Group. Journal Of Clinical Oncology 2017, 35: jco.2016.67.654. PMID: 28240974, PMCID: PMC5455599, DOI: 10.1200/jco.2016.67.6544.Peer-Reviewed Original ResearchConceptsMalignant germ cell tumorsEvent-free survivalCycles of PEBEFS ratesGerm cell tumorsOncology GroupCell tumorsExtracranial malignant germ cell tumorsReduction of therapyChildren's Oncology GroupSingle-arm trialLow-stage tumorsHigh-stage tumorsAdministration of cisplatinEligible patientsComparable patientsHistorical cohortPatientsTumorsStatistical significanceComparable childrenPhase 3ChildrenP-valueOne-sided p-value
2014
Surveillance After Initial Surgery for Pediatric and Adolescent Girls With Stage I Ovarian Germ Cell Tumors: Report From the Children's Oncology Group
Billmire DF, Cullen JW, Rescorla FJ, Davis M, Schlatter MG, Olson TA, Malogolowkin MH, Pashankar F, Villaluna D, Krailo M, Egler RA, Rodriguez-Galindo C, Frazier AL. Surveillance After Initial Surgery for Pediatric and Adolescent Girls With Stage I Ovarian Germ Cell Tumors: Report From the Children's Oncology Group. Journal Of Clinical Oncology 2014, 32: 465-470. PMID: 24395845, PMCID: PMC4876316, DOI: 10.1200/jco.2013.51.1006.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAlpha-FetoproteinsAntineoplastic Combined Chemotherapy ProtocolsBleomycinChildChild, PreschoolCisplatinDisease-Free SurvivalEtoposideFemaleHumansInfantInfant, NewbornKaplan-Meier EstimateNeoplasm Recurrence, LocalNeoplasm StagingNeoplasm, ResidualNeoplasms, Germ Cell and EmbryonalOvarian NeoplasmsRadiographyRisk FactorsSalvage TherapyTime FactorsTreatment OutcomeConceptsMalignant ovarian germ cell tumorsStage I malignant ovarian germ cell tumorsOvarian germ cell tumorsEvent-free survivalGerm cell tumorsOverall survivalAlpha-fetoproteinRecurrent diseaseOncology GroupCell tumorsSuccessful Salvage ChemotherapyTumor marker elevationPercent of patientsKaplan-Meier methodChildren's Oncology GroupSerum tumor markersPredominant histologySalvage chemotherapyInitial surgeryMarker elevationMetastatic diseaseSurgical resectionMedian timeYolk sacTumor markers